The role of RAS modification for primary and secondary stroke prevention.

Abstract

Clinical trial results indicate that the choice of antihypertensive agent can be a determinant of stroke protection, independent of blood pressure (BP) reduction. Angiotensin-converting enzyme inhibitors (ACE-Is) are effective for BP control and stroke protection, but their use may be limited by patient tolerability. Angiotensin receptor blockers appear to provide similar BP control compared with ACE-Is and may also offer the clinician the added benefit of primary and secondary stroke prevention, with the potential for fewer tolerability issues.

• Authors: Dan J Fintel
• Journal: Postgraduate medicine (Postgrad Med) Vol. 121 Issue 4 Pg. 115-22 (Jul 2009) ISSN: 1941-9260 [Electronic] England
• PMID: 19641277 (Publication Type: Journal Article, Review)

Chemical References

• Angiotensin II Type 1 Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents

Topics

• Angiotensin II Type 1 Receptor Blockers (therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Blood Pressure
• Humans
• Renin-Angiotensin System (physiology)
• Risk Factors
• Stroke (etiology, physiopathology, prevention & control)